oral+semaglutide+approval Oral Semaglutide Approved to Reduce the Risk of Cardiovascular Events Novo Nordisk's weight-loss pill wins

Surmeier, D

Retrieved 2023-07-11

And there's not really anything that we've discovered that makes us aware of who would be at risk

[1] Clinical trials have demonstrated substantial reductions in hemoglobin A1c (HbA1c) levelsoften exceeding 2% from baselinealong with clinically meaningful weight loss that varies by dose and indication (approximately 15-20% of body weight in obesity trials at the highest doses, with lower percentages typically seen in diabetes trials)

HSS Journal, 21(4), 485-495

Having more active glutathione on board is a good thing for longevity, disease prevention, and the slowing of disease progression